Results 151 to 160 of about 430,791 (198)

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Context-dependent interactions between variable-loop pulsed field ablation and cardiac implantable electronic devices: a controlled preclinical study. [PDF]

Eur Heart J Open
Takigawa M, Kato R, Kawamura I, Toda M, Honda M, Negishi M, Tateishi R, Yamaguchi J, Goto K, Nishimura T, Tao S, Miyazaki S, Sasano T.   +12 more
europepmc   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model‐based simulation of the positioning imatinib for pulmonary arterial hypertension trial

British Journal of Clinical Pharmacology, EarlyView.
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said, Robert B. de Mooij, Dian Jiao, Reitze J. Ovelgonne, Rami Biram, Juan Delgado‐SanMartin, Alexander M. K. Rothman, Sofia S. Villar, Andreas A. Roussakis, Jurjan Aman, Ron A. A. Mathôt, Eleonora L. Swart, Martin R. Wilkins, Imke H. Bartelink   +13 more
wiley   +1 more source

CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension

British Journal of Clinical Pharmacology, EarlyView.
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien, Burabha Pussadhamma, Sirimas Kanjanawart, Thikhumporn Areesinpitak, Nontaya Nakkam, Chingching Foocharoen, Wichittra Tassaneeyakul, Suda Vannaprasaht   +7 more
wiley   +1 more source

Retained tunneled dialysis catheter presenting with complete exit site healing: A case report. [PDF]

SAGE Open Med Case Rep
Ostroff M, Shenasan P, Skoutsomitis D, Elzomor H, Danks J.   +4 more
europepmc   +1 more source

Compliant hydrogel cuff coating with real‐time pressure monitoring and antibiofilm capabilities for ventilator‐associated pneumonia prophylaxis

BMEMat, EarlyView.
A soft‐compliant hydrogel cuff coating combines real‐time pressure monitoring with intrinsic antibacterial activity for prophylaxis of ventilator‐associated pneumonia. A flexible pressure‐sensing patch is embedded in the coating to enable wireless dynamic monitoring of endotracheal cuff pressure through Bluetooth.
Jin Chai, Yifu Tan, Jiaheng Liang, Shen Liu, Jiabin Zhao, Shanbo Ma, Chunxin Liu, Minghua Du, Mark Selvan, Xiaopeng Shi, Liqiang Song, Peng Li   +11 more
wiley   +1 more source

Hyperbranched poly‐L‐lysine surface‐engineered bioprosthetic heart valves with anti‐calcification, anti‐infection, and durability

BMEMat, EarlyView.
The challenges of bioprosthetic heart valves (BHV) with respect to calcification, infection, and poor durability are tackled by surface engineering of hyperbranched poly‐L‐lysine (HBPL), providing a translational solution to improve long‐term valve performance.
Pai Peng, Dongchao Qiu, Yongyuan Kang, Qiaoxuan Wang, Xuelong Wang, Boyana Parvanova, Miroslav Karabaliev, Changyou Gao   +7 more
wiley   +1 more source

Fluoroless Workflow for Pulsed Field Ablation of Atrial Fibrillation Using the Sphere-9 and VARIPULSE Catheters. [PDF]

J Clin Med
Kour R, Costa A, Jamal S, Hakim F, Imtiaz H, Kanjwal K.   +5 more
europepmc   +1 more source

Engineered immunostimulatory H2O2‐producing microreactors driven by yeast as localized living cancer therapeutics

BMEMat, EarlyView.
Engineered yeast microreactors that produce H2O2 within tumors enable selective cancer cell killing while releasing immunostimulatory components, effectively suppressing local tumor growth and activating systemic antitumor immunity, with further efficacy enhanced by anti‐PD‐1 therapy and transarterial embolization.
Wenqian He, Chunjie Wang, Minming Chen, Weihao Yang, Bin Yu, Yuhang Hu, Hengze Ding, Yifan Yan, Zhijuan Yang, Liangzhu Feng   +9 more
wiley   +1 more source